Pancreatic Cancer Screening for At-Risk Individuals (Pancreas Scan Study): Yield, Harms, and Outcomes from a Prospective Multicenter Study

Ishani Shah, Andy Silva-Santisteban, Katharine A. Germansky, Arvind Trindade, Kara L. Raphael, Vladimir Kushnir, Rishi Pawa, Girish Mishra, Jiannis Anastasiou, Sumant Inamdar, Benjamin Tharian, Mohammad Bilal, Mandeep S. Sawhney

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

INTRODUCTION:Guidelines endorse pancreatic cancer screening in genetically susceptible individuals. We conducted a prospective, multicenter study to determine yield, harms, and outcomes of pancreatic cancer screening.METHODS:All high-risk individuals undergoing pancreatic cancer screening at 5 centers from 2020 to 2022 were prospectively enrolled. Pancreas findings were designated as low-risk (fatty or chronic pancreatitis-like changes), intermediate-risk (neuroendocrine tumor [NET] <2 cm or branch-duct intraductal papillary mucinous neoplasm [IPMN]), or high-risk lesions (high-grade pancreatic intraepithelial neoplasia/dysplasia, main-duct IPMN, NET >2 cm, or pancreatic cancer). Harms from screening included adverse events during screening or undergoing low-yield pancreatic surgery. Annual screening was performed using endoscopic ultrasound and or magnetic resonance cholangiopancreatography. Annual screening for new-onset diabetes using fasting blood sugar was also performed (ClinicalTrials.gov: NCT05006131).RESULTS:During the study period, 252 patients underwent pancreatic cancer screening. Mean age was 59.9 years, 69% were female, and 79.4% were White. Common indications were BRCA 1/2 (36.9%), familial pancreatic cancer syndrome kindred (31.7%), ataxia telangiectasia mutated (3.5%), Lynch syndrome (6.7%), Peutz-Jeghers (4.3%), and familial atypical multiple mole melanoma (3.5%). Low-risk lesions were noted in 23.4% and intermediate-risk lesions in 31.7%, almost all of which were branch-duct IPMN without worrisome features. High-risk lesions were noted in 2 patients (0.8%), who were diagnosed with pancreas cancer at stages T2N1M0 and T2N1M1. Prediabetes was noted in 18.2% and new-onset diabetes in 1.7%. Abnormal fasting blood sugar was not associated with pancreatic lesions. There were no adverse events from screening tests, and no patient underwent low-yield pancreatic surgery.DISCUSSION:Pancreatic cancer screening detected high-risk lesions with lower frequency than previously reported. No harms from screening were noted.

Original languageEnglish
Pages (from-to)1664-1670
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume118
Issue number9
DOIs
StatePublished - Sep 1 2023

Keywords

  • endoscopic ultrasound
  • intraductal papillary mucinous neoplasm
  • magnetic resonance imaging
  • pancreatic cancer
  • screening

Fingerprint

Dive into the research topics of 'Pancreatic Cancer Screening for At-Risk Individuals (Pancreas Scan Study): Yield, Harms, and Outcomes from a Prospective Multicenter Study'. Together they form a unique fingerprint.

Cite this